Purple Biotech Ltd Stock Price, News & Analysis

Purple Biotech Ltd. (NASDAQ/TASE: PPBT) recently inaugurated its Scientific Advisory Board (SAB), comprised of three experts from oncology and cancer research. This initiative aims to enhance the company's strategic direction in developing innovative cancer therapies targeting tumor immune evasion and drug resistance. The SAB includes distinguished members: Eyal Gottlieb, PhD, from MD Anderson; Steven Maron, MD, from Memorial Sloan Kettering; and Sunil Sharma, MD, MBA, from Translational Genomics. The board will assist management by providing scientific guidance on clinical trials and R&D activities, which is expected to aid in the advancement of the company’s oncology pipeline, including therapies like NT219 and CM24.

Purple Biotech (NASDAQ/TASE: PPBT) has unveiled promising preclinical data at the American Association for Cancer Research (AACR) Annual Meeting 2023, held on April 18, 2023. The results highlight the effectiveness of NT219, a novel small molecule dual inhibitor targeting IRS1/2 and STAT3, in enhancing immune responses in the tumor microenvironment (TME).

Key findings include:

• NT219 significantly increased PDL1 expression in resistant melanoma cells and enhanced anti-PD1 therapy effectiveness.
• In combination with anti-PD1 or anti-CTLA4, NT219 drove significant increases in activated CD8 cytotoxic T and NK cells while decreasing immunosuppressive cell populations.
• NT219 showed lasting effects on IRS1 and STAT3 phosphorylation, linked to tumor drug resistance.

The results indicate NT219 could convert resistant tumors into responders for immune checkpoint blockade therapies.

Purple Biotech (NASDAQ/TASE: PPBT) announced the participation of Dr. Amir Horowitz at Canaccord Genuity's 2023 Horizons in Oncology Virtual Conference on April 20, 2023. He will present on the newly acquired Tri-specific antibody as part of the panel titled New & better Approaches for Oncology Targets. The presentation will take place from 2:00-2:45 PM ET, and a live webcast will be accessible to registered attendees.

Purple Biotech is a clinical-stage company focused on therapies that combat tumor immune evasion and drug resistance. Its oncology pipeline includes NT219, CM24, and IM1240, addressing various solid tumors. The ongoing studies involve NT219, which targets IRS1/2 and STAT3, and CM24, a monoclonal antibody in collaboration with Bristol Myers Squibb.

Purple Biotech Ltd. (NASDAQ/TASE: PPBT) announced that CEO Gil Efron is on medical leave due to an accident, with Isaac Israel appointed as acting CEO. The company emphasizes that its business plan and clinical development programs will proceed as scheduled. The announcement reassures stakeholders about continuity and stability during this transition. Purple Biotech focuses on developing therapies that tackle tumor immune evasion and drug resistance, with a pipeline including NT219 and CM24 in various clinical stages. The company remains committed to its 2023 objectives despite the leadership change.